Xtl biopharmaceuticals ltd (XTLB)
CashFlow / Yearly
Dec'17Dec'16Dec'15
Cash flows from operating activities:
Loss for the year

-781

-2,545

-4,311

Adjustments to reconcile loss to net cash used in operating activities (a)

-344

813

2,450

Net cash used in operating activities

-1,125

-1,732

-1,861

Cash flows from investing activities:
Deconsolidation of subsidiary

0

0

-55

Proceeds from maturity of restricted deposit

0

0

21

Investment in restricted deposit

0

0

10

Investment in short-term bank deposit

-2,500

0

0

Interest from bank deposit

4

0

0

Purchase of property and equipment

0

2

2

Proceeds from sale of property and equipment

1

0

0

Purchase of intangible assets

0

64

64

Net cash used in investing activities

-2,495

-66

-110

Cash flows from financing activities:
Proceeds from issuance of units comprise from ordinary shares and warrants (net of issuance costs of $408 thousands)

4,892

0

3,559

Transactions with non-controlling interests in a subsidiary

0

0

20

Net cash provided by financing activities

4,892

0

3,579

Increase (decrease) in cash and cash equivalents

1,272

-1,798

1,608

Losses from exchange rate differences on cash and cash equivalents

-2

0

-2

Reclassification of cash in subsidiary to assets of disposal group held for sale

0

0

52

Adjustments to reconcile loss to net cash used in operating activities:
Income and expenses not involving operating cash flows:
Depreciation and amortization

1

3

7

Loss from disposal of property and equipment

8

0

5

Loss from disposal of intangible assets

0

0

5

Issuance costs related to warrants granted to investors

329

0

0

Revaluation of warrants to purchase ADS's

-765

0

0

Share-based payment transactions to employees and non-employees

40

182

148

Gains from exchange rate differences on cash and cash equivalents

-2

0

-2

Disposal of investment in subsidiary

0

0

689

Impairment of intangible assets

0

-848

-1,604

Interest received

-4

0

0

Other financial expenses (income)

7

0

-6

Net income and expenses not involving cash flows

-396

1,033

2,466

Changes in operating asset and liability items:
Decrease (increase) in other accounts receivable

209

-114

36

Decrease in trade payables

-13

-101

-117

Increase (decrease) in other accounts payable

-144

-5

65

Net operating asset and liability

52

-220

-16

Net cash provided by (used in) operating activities

-344

813

2,450

Non-cash transactions:
Purchase of intangible asset

127

0

0

Interest on bank deposit

13

0

0

Share-based payment to third party

0

54

84

De-consolidation of subsidiary:
Non-current assets held for sale

0

0

507

Non-current liabilities held for sale

0

0

449

Disposal of treasury shares

0

0

1,501

Negative premium from disposal of treasury shares

0

0

587

Investment in associate at fair value

0

0

-482

Loss from disposal of subsidiary

0

0

-464

Non-controlling interests

0

0

26

Net de-consolidation of subsidiary

0

0

0